Prochymal^® phase 3 clinical trial For the treatment of Steroid-Refractory Acute GvHD

Enrollment for this Trial has been completed

The objective of this Phase 3 study is to evaluate the efficacy and safety of Prochymal in those patients who are not responding to steroid therapy. It is expected that the stem cells will distribute to areas of inflammation where they can repair the damaged tissue.

Trial Overview

Click Here for more information

If you have questions about this clinical program, please email us at GvHD@Osiris.com